Engineering Partnership for Holly Springs Facility
Engineering consultant Jacobs has secured a significant contract with Fujifilm Diosynth Biotechnologies to support the $1.2 billion expansion of a biotechnology facility in Holly Springs, North Carolina, USA. This collaboration marks a continuation of Jacobs’ involvement, having originally supported the construction of the Holly Springs site, which commenced in 2021. Jacobs will now provide engineering, procurement, and construction management services for this extensive expansion project.
Enhancing Biopharmaceutical Manufacturing Capabilities
The expansion includes the construction of a large-scale cell culture contract manufacturing facility. This state-of-the-art facility will offer drug substance manufacturing, automated fill-finish, assembly, packaging, and labeling services for global biopharmaceutical clients. The new development will significantly enhance the site’s manufacturing capabilities and capacity.
Substantial Infrastructure Growth by 2028
The expansion project will add eight 20,000-litre cell culture bioreactors and an additional 400,000 square feet (37,161 square meters) of manufacturing space by 2028. This is in addition to the eight bioreactors for bulk drug substance already planned in the initial phase, which is expected to be completed by 2025. Fujifilm Diosynth Biotechnologies’ chief operating officer and executive vice president of operations, Kenneth Bilenberg, highlighted that once complete, the Holly Springs site will be one of the largest, end-to-end cell culture contract manufacturing facilities in North America.
